The conclusion of the research suggests that NVC-422 is a powerful agent of rapid-acting, broad-spectrum antimicrobial that kills P. mirabilis and thereby inhibit the formation of struvite crystals and subsequent catheter blockage, said Dr. Najafi.Dimitri Debabov cell head and Microbiology Pharmaceutical NovaBay investigated the potential use of a non–antibiotics, anti-infective compound NVC -422. The company uses an in vitro model to simulate a catheterized bladder infected with P. mirabilis resulting in struvite encrustation. NVC-422 was able to inhibit bacterial growth and the formation of struvite from these rooms for bladder catheterization to 144 hours compared to saline control, which has locked in 46 hours. Electron microscopy confirmed that these catheters have been blocked due to the accumulation of biofilm and struvite.
NovaBay estimated that over 300,000 patients suffering from wounds and spinal cord injury or quadriplegia or paraplegia resulting from the use of Foley catheters. These patients are at risk every day for the development of catheter-associated. P. NovaBay non-antibiotic anti-infective deals directly with this and other bacteria within the bladder, without the opportunity to develop strength and maintain the patency of the catheter.
Patients with long-term bladder catheters are often faced with a potentially serious complication caused by Gram-negative bacteria Proteus mirabilis that can colonize the catheter. Another complication caused by P. mirabilis is the formation of biofilm and encrustation of the catheter with struvite crystals in urine flow resulting in slowed or blocked. If left open the lock and bacteriuria can lead to sepsis.